


Vardenafil hydrochloride

Cat. No.:	HY-B0442A
CAS No.:	224785-91-5
Molecular Formula:	C ₂₃ H ₃₃ ClN ₆ O ₄ S
Molecular Weight:	525.06
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (190.45 mM; Need ultrasonic)
 H₂O : ≥ 100 mg/mL (190.45 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	1.9045 mL	9.5227 mL	19.0454 mL
	5 mM	0.3809 mL	1.9045 mL	3.8091 mL	
	10 mM	0.1905 mL	0.9523 mL	1.9045 mL	

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 120 mg/mL (228.55 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.76 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.76 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.76 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Vardenafil hydrochloride is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil hydrochloride can be used for the research of erectile dysfunction^{[1][2]}.

IC₅₀ & Target	PDE5 0.7 nM (IC ₅₀)	PDE6 11 nM (IC ₅₀)	PDE1 180 nM (IC ₅₀)
In Vitro	Vardenafil specifically inhibits the hydrolysis of cGMP by PDE5 with an IC ₅₀ of 0.7 nM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

CUSTOMER VALIDATION

- Anim Cells Syst (Seoul). 2019 May 16;23(3):155-163.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ashour AE, et al. Vardenafil dihydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:515-544.

[2]. Saenz de Tejada I, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001;13(5):282-290.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA